Mequon, Wisc.-based Titan Spine saw a 51 percent increase in sales of its Endoskeleton interbody fusion devices in 2015.
Here are five points:
1. In 2015, Titan Spine had $33.5 million in global sales.
2. The company's fourth quarter sales equated to annualized run rate of $43.1 million.
3. Titan Spine sold about 10,000 Endoskeleton implants in 2015.
4. The company has more than 400 hospital customers globally and more than 110 distributors.
5. Titan Spine plans to release its nanoLOCK surface technology, which is the only FDA-cleared nanotechnology for spine.
"The considerable progress Titan Spine achieved in 2015 is a reflection of the interbody device market's accelerating shift toward titanium implants, which is due, at least in part, to our continually expanding science and research," said Peter Ullrich, chief executive officer, Titan Spine.